Objectives Polymyxins are currently the last-resort treatment against multi-drug resistant
Gram-negative bacterial infections, but plasmid-mediated mobile polymyxin resistance …

Polymyxins remain important last-line antibiotics against multidrug-resistant Gram-negative
bacteria. Unfortunately, polymyxin resistance is emerging and the mobile polymyxin …

Polymyxins were recently approved for the clinical treatment of carbapenem-resistant
Enterobacteriaceae (CRE) infections in China. The aim of this study was to determine the …

Polymyxins are last-resort antimicrobial agents used to treat infections caused by
carbapenem-resistant Enterobacteriaceae. Due to the worldwide dissemination of polymyxin …

Polymyxin is the final choice for the treatment of gram-negative bacteria such as
Acinetobacter baumannii, Pseudomonas aeruginosa and Klebsiella pneumoniae. In 2015 …

The emergence of the plasmid-mediated colistin resistance gene mcr-1 has led to serious
multidrug-resistant (MDR) Enterobacteriaceae infections, which are a great threat to the …

Objectives The discovery of mobile colistin resistance mcr-1, a plasmid-borne polymyxin
resistance gene, highlights the potential for widespread resistance to the last-line …

Polymyxins (polymyxin E/colistin and polymyxin B) are considered the last-resort therapy
against carbapenem-resistant Enterobacterales; however, the resistance of …

The rapid increase of carbapenem resistance in Gram-negative bacteria has resurrected the
importance of the polymyxin antibiotics. The recent discovery of plasmid-mediated …

Objective To describe the molecular mechanisms of polymyxins resistance in five
Enterobacteriaceae clinical isolates from a tertiary hospital of Recife, Brazil. Methods The …